Dr Amy Buckley

Lecturer , Pharmacology - School of Health

Phone: +61 2 6773 3492

Email: Amy.Buckley@une.edu.au

Biography

Amy completed her PhD studies at theTrinity Translational Medicine Institute, Trinity College Dublin in 2019 under the supervision of Prof Jacintha O’Sullivan investigating the potential for novel small molecule compounds to enhance radiosensitivity in oesophageal adenocarcinoma.  Amy then travelled to Australia where she worked at Queensland University of Technology as a post doctoral researcher with Prof David Waugh based at the  Translational Research Institute in Brisbane. Amy then spent 4 years working with the Australian Pesticides and Veterinary Medical Authority as Senior Evaluator in the chemical review team before joining UNE in 2024.

Qualifications

BSc (Hons) Major in Pharmacology, University College Dublin.  PhD, Trinity College Dublin

Teaching Areas

Pharmacology

Primary Research Area/s

Oesophageal Adenocarcinoma; Treatment Resistance; Radioresistance; Drug Development

Research Supervision Experience

Co-supervision of MSc students undertaking masters in Translational Oncology at Trinity College Dublin.

Publications

  1. Buckley, A.M., Lynam-Lennon, N., O’Neill, H. et al. Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol 17, 298–313 (2020).
  2. Buckley, A. M., Bibby, B. AS., Dunne, M. R., Kennedy, S. A., Davern, M. B., Kennedy, B.N., Maher, S.G., and O'Sullivan, J. Characterisation of an isogenic model of cisplatin resistance in oesophageal adenocarcinoma cells. Pharmaceuticals, 2019. 12(1): p. 33.
  3. Buckley, A. M., Dunne, M. R., Lynam-Lennon, N., Kennedy, S. A., Cannon, A., Reynolds, A. L., Maher, S.G., Reynolds, J.V., Kennedy, B.N. and O'Sullivan, J. (2019). Pyrazinib (P3),[(E)-2-(2-Pyrazin-2-yl-vinyl)-phenol], a small molecule pyrazine compound enhances radiosensitivity in oesophageal adenocarcinoma. Cancer letters, 447, 115- 129.
  4. Buckley, A. M., Lynam-Lennon, N., Kennedy, S. A., Dunne, M. R., Aird, J. J., Foley, E. K., Clarke, N., Ravi, N., O'Toole, D., Reynolds, J. V., Kennedy, B. N., and O'Sullivan, J. (2018). Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma. Oncotarget, 9(72), 33634-33647.
  5. Buckley, A.M., Dunne, M.R., Morrissey, M.E., Kennedy, S.A., Nolan, A., Davern, M., Foley, E.K., Clarke, N., Lysaght, J., Ravi, N. and O’Toole, D., 2020. Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib. Scientific reports, 10(1), pp.1-16.
  6. O’Connell, J., Doherty, J., Buckley, A., Cormican, D., Dunne, C., Hartery, K., Larkin, J., MacCarthy, F., McCormick, P., McKiernan, S. and Mehigan, B., 2022. Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis. Intestinal Research, 20(3), p.381
  1. Marcone S, Buckley A, Ryan CJ, McCabe M, Lynam-Lennon N, Matallanas D, O Sullivan J, Kennedy S. Proteomic signatures of radioresistance: Alteration of inflammation, angiogenesis and metabolism-related factors in radioresistant oesophageal adenocarcinoma. Cancer Treat Res Commun. 2021;27:100376.
  2. Heeran, A.B., McCready, J., Dunne, M.R., Donlon, N.E., Nugent, T.S., Bhardwaj, A., Mitchelson, K.A., Buckley, A.M., Ravi, N., Roche, H.M. and Reynolds, J.V., 2021. Opposing Immune-Metabolic Signature in Visceral Versus Subcutaneous Adipose Tissue in Patients with Adenocarcinoma of the Oesophagus and the Oesophagogastric Junction. Metabolites, 11(11), p.768.
  3. Heeran, A.B., Berrigan, H.P., Buckley, C.E., Bottu, H.M., Prendiville, O., Buckley, A.M., Clarke, N., Donlon, N.E., Nugent, T.S., Durand, M. and Dunne, C., 2021. Radiation-induced Bystander Effect (RIBE) alters mitochondrial metabolism using a human rectal cancer ex vivo explant model. Translational oncology, 14(1), p.100882.
  4. Kennedy, S.A., Morrissey, M.E., Dunne, M.R., O’Connell, F., Butler, C.T., Cathcart, M.C., Buckley, A.M., Mehigan, B.J., Larkin, J.O., McCormick, P. and Kennedy, B.N., 2020. Combining 1, 4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors. BMC cancer, 20(1), pp.1-14.
  5. Butler, C.T., Kennedy, S.A., Buckley, A., Doyle, R., Conroy, E., Gallagher, W.M., O’Sullivan, J. and Kennedy, B.N., 2019. 1, 4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours. Oncotarget, 10(38), p.3725.
  6. Slater, K., Hoo, P. S., Buckley, A. M., Piulats, J. M., Villanueva, A., Portela, A., and Kennedy, B. N. (2018). Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma. Cancer and Metastasis Reviews, 37(2-3), 335-345.
  7. Butler, C.T., Kennedy, S.A., Buckley, A., Doyle, R., Conroy, E., Gallagher, W.M., O’Sullivan, J. and Kennedy, B.N., 2019. 1, 4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours. Oncotarget, 10(38), p.3725.